AstraZeneca (AZ) has divested the US rights to two of its chronic obstructive pulmonary disease (COPD) drugs to Circassia in a deal worth up to US$300 M. The deal includes previously marketed Tudorza Pressair (aclidinium bromide), a long-acting muscarinic antagonist (LAMA) and Duaklir Genuair (aclidinium bromide and formoterol fumarate dihydrate) a long-acting beta-agonist (LABA/LAMA combination approved in the EU and in Phase III development in the US. AZ will acquire an equity stake of US$50 M in Circassia and will receive US$100 M on either US approval of Duaklir or by 30 June 2019, which is the sooner.